Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.80 +1.00 (+6.76%)

Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist

Price and Volume

Volume	6,010,673
Open	14.93
Bid (Size)	15.79 (100)
Ask (Size)	16.00 (500)
Prev. Close	14.80
Today's Range	14.86 - 16.42
52wk Range	12.07 - 29.23
Shares Outstanding	97,381,774
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗

October 26, 2026

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

Via MarketBeat

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

October 25, 2026

From Summit Therapeutics

Via Business Wire

Performance

52-Week Range 45.9% below 52-week high

15.80

12.0752W Low 29.2352W High

1 Week 4.5% below 1-week high

14.401W Low 16.551W High

Summit Therapeutics Inc. - Common Stock (SMMT) traded between $12.07 and $29.23 over the past 52 weeks and last traded at $15.80, 45.9% below its 52-week high. Over the past week it ranged between $14.40 and $16.55.

Past 12 Months

+3.1%

-8.5%

+21.1%

-6.9%

-9.8%

-13.3%

1W +$0.47

1M -$1.47

3M +$2.76

6M -$1.18

YTD -$1.72

1Y -$2.42

SMMT was -13.3% over the past year, -6.9% over six months, -9.8% year to date, +3.1% in the last week.

12 Months vs Market

SMMT

-13.3%

DIA

+9.2%

SPY

+10.4%

QQQ

+8.4%

IWM

+14.0%

Over the past 12 months SMMT returned -13.3% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 1.00× 3-mo avg

Today 6,010,673 3-mo avg 6.0M

4.0M

5.1M

6.0M

5.6M

YTD

4.6M

4.3M

SMMT most recently traded 6,010,673 shares against a 3-month average daily volume of 6.0M.

More News

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

October 23, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗

July 23, 2026

Via Chartmill

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

October 22, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

October 21, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

October 19, 2026

From Summit Therapeutics

Via Business Wire

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

October 05, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

October 02, 2026

From Summit Therapeutics

Via Business Wire

These stocks that are showing activity before the opening bell on Tuesday. ↗

September 29, 2026

Via Chartmill

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

September 28, 2026

From Summit Therapeutics

Via Business Wire

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

September 22, 2026

From Summit Therapeutics

Via Business Wire

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

September 15, 2026

From Summit Therapeutics

Via Business Wire

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

September 13, 2026

From Summit Therapeutics

Via Business Wire

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

September 02, 2026

From Summit Therapeutics

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 26, 2026

Via Benzinga

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

August 25, 2026

From Summit Therapeutics

Via Business Wire

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

August 25, 2026

From Summit Therapeutics

Via Business Wire

GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗

August 24, 2026

Via The Motley Fool

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

August 12, 2026

From Summit Therapeutics

Via Business Wire

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

August 06, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

August 05, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Q2 Earnings Call Highlights ↗

July 23, 2026

Via MarketBeat

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

July 23, 2026

From Summit Therapeutics

Via Business Wire

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

July 22, 2026

From Summit Therapeutics

Via Business Wire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?

Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Summit Therapeutics Inc. - Common Stock trade on?

Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?

The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market

What is the current price of Summit Therapeutics Inc. - Common Stock?

The current price of Summit Therapeutics Inc. - Common Stock is 15.80

When was Summit Therapeutics Inc. - Common Stock last traded?

The last trade of Summit Therapeutics Inc. - Common Stock was at 11/03/26 04:00 PM ET

What is the market capitalization of Summit Therapeutics Inc. - Common Stock?

The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.54B

How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?

Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.